drugset / Trial / NCT00437489

A Clinical Trial Comparing The Efficacy And Safety Of 2 Different Initial Dose Prescriptions For Exubera.

NCT00437489

Phase 4 Terminated 49 enrolled Pfizer
RandomizedParallel-groupOpen-labelTreatment

Summary

The primary objective of this study is to assess whether a simple initial dose prescription of inhaled insulin (Exubera) achieves glycemic control (HbA1c) after 16 weeks that is non-inferior compared to the standard weight-based formula.

Timeline

Start
2007-06
Primary completion
2007-12
Completion
2007-12

Drugs

EvaluationDrugModalityDoseRoute
Subject Insulin Protein / enzyme biologic 0.05 mg/kg Inhaled
Subject Insulin Protein / enzyme biologic 1 mg Inhaled